The ATOS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ATOS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ATOS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ATOS Detailed Price Forecast - CNN Money||View ATOS Detailed Summary - Google Finance|
|View ATOS Detailed Summary - Yahoo! Finance||View ATOS Stock Research & Analysis - Zacks.com|
|View ATOS Trends & Analysis - Trade-Ideas||View ATOS Major Holders - Barrons|
|View ATOS Call Transcripts - NASDAQ||View ATOS Breaking News & Analysis - Seeking Alpha|
|View ATOS Annual Report - CompanySpotlight.com||View ATOS OTC Short Report - OTCShortReport.com|
|View ATOS Fundamentals - TradeKing||View ATOS SEC Filings - Bar Chart|
|View Historical Prices for ATOS - The WSJ||View Performance/Total Return for ATOS - Morningstar|
|View the Analyst Estimates for ATOS - MarketWatch||View the Earnings History for ATOS - CNBC|
|View the ATOS Earnings - StockMarketWatch||View ATOS Buy or Sell Recommendations - MacroAxis|
|View the ATOS Bullish Patterns - American Bulls||View ATOS Short Pain Metrics - ShortPainBot.com|
|View ATOS Stock Mentions - StockTwits||View ATOS Stock Mentions - PennyStockTweets|
|View ATOS Stock Mentions - Twitter||View ATOS Investment Forum News - Investor Hub|
|View ATOS Stock Mentions - Yahoo! Message Board||View ATOS Stock Mentions - Seeking Alpha|
|View Insider Transactions for ATOS - SECform4.com||View Insider Transactions for ATOS - Insider Cow|
|View ATOS Major Holdings Summary - CNBC||View Insider Disclosure for ATOS - OTC Markets|
|View Insider Transactions for ATOS - Yahoo! Finance||View Institutional Holdings for ATOS - NASDAQ|
|View ATOS Stock Insight & Charts - FinViz.com||View ATOS Investment Charts - StockCharts.com|
|View ATOS Stock Overview & Charts - BarChart||View ATOS User Generated Charts - Trading View|
An Interview with Atossa CEO Steven Quay MD, Ph.D. Titled, "What Is Gynecomastia?"
Posted on Friday September 14, 2018
SAN FRANCISCO, CA / ACCESSWIRE / September 14, 2018 / The Groundwork Forum Podcast aims to bring together leaders from all disciplines all over the world to join its Global Community to consider new perspectives ...
Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen
Posted on Thursday September 13, 2018
Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, reported preliminary results from its Phase 1 dose- escalation study of its proprietary topical Endoxifen in male subjects. Safety: There were no clinically significant safety signals and no clinically significant adverse events in participants receiving topical Endoxifen. “Based on these positive preliminary results, we are advancing our topical Endoxifen into a Phase 2 study to reduce gynecomastia in men starting prostate cancer therapy,” commented Dr. Steven C. Quay, CEO and President. “We anticipate retaining a clinical research organization to manage that study in the fourth quarter 2018.
Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, will host a conference call on September 13, 2018 at 10 am EDT to discuss preliminary results from its Phase 1 dose-escalation study of its proprietary topical Endoxifen in male subjects. The Phase 1 study was a double-blind, placebo-controlled, repeat dose study of 24 healthy male subjects. Atossa assessed safety, tolerability and the pharmacokinetics of proprietary formulations of topical Endoxifen at varying dose levels over 28 days. Callers should ask to be joined into the Atossa Genetics call.
''Robust Economy, Resilient Market''
Posted on Thursday August 23, 2018
SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2018 / Vista Partners ("Vista") has published August's FREE Macroeconomic & Investment Monthly Newsletter, "Robust Economy, Resilient Market." ...